We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Again Says ‘No’ to Vertex’s Cystic Fibrosis Drug, Citing Modest Benefits
NICE Again Says ‘No’ to Vertex’s Cystic Fibrosis Drug, Citing Modest Benefits
Despite appeals, the UK’s drug pricing watchdog has held firm against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, once again noting its modest short-term benefits to lung function and unknown long-term improvements.